argenx reports USD 506 million profit as argenx stock trades at EUR 779.30

Published on 10/23/2026 at 10:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

argenx posts USD 506 million profit in the third quarter. argenx stock trades at EUR 779.30 on October 23, 2026 as results are due February 25, 2027.

Third quarter growth and future dates

argenx generated USD 1.7 billion in product net sales in the third quarter of 2026, up 54.00 percent year over year.
Third-quarter profit reached USD 506 million, compared with USD 344 million in the third quarter of 2025.
argenx stock was trading at EUR 779.30 at 10:10 a.m. CEST at Lang & Schwarz on October 23, 2026.
Full-year 2026 results are scheduled for February 25, 2027.

Extremmakro: Iridisierende blaue und violette Flüssigkeitstropfen auf einem Glasobjektträger, kristallscharfe Mitte mit weichem Bokeh, wissenschaftliche Abstraktion — Argenx NL0010832176 Extremmakro zeigt irisierende Flüssigkeitstropfen auf einem wissenschaftlichen Glas-Objektträger unter Laborlicht, Illustration mit AI erstellt.

argenx (ISIN NL0010832176) reported USD 506 million in profit for the third quarter of 2026, while argenx stock was trading at EUR 779.30 at Lang & Schwarz on October 23, 2026 at 10:10 a.m. CEST. The company said on October 22, 2026 that product net sales reached USD 1.7 billion, up 54.00 percent from the third quarter of 2025, according to GlobeNewswire.

VYVGART drives the quarter

The results show how strongly argenx still depends on VYVGART while the company builds additional products and indications. VYVGART product net sales reached USD 1.7 billion in the third quarter, compared with USD 1.1 billion in the same period of 2025. Total operating income was USD 1.8 billion, versus USD 1.2 billion a year earlier.

Operating profit increased to USD 486 million from USD 346 million in the third quarter of 2025. Selling, general and administrative expenses included approximately USD 150 million of acquisition-related costs connected with Forte Biosciences, giving investors a concrete measure of the near-term investment burden. Cash, cash equivalents and current financial assets totaled USD 3.7 billion as of September 30, 2026.

What does the pipeline add?

The company is using the VYVGART franchise to finance a wider immunology pipeline. The official update said Phase 3 results for empasiprubart in multifocal motor neuropathy are expected in December 2026, while FB102 is advancing to Phase 3 development in celiac disease. An additional registrational study in dermatomyositis is also planned after the ALKIVIA results.

The immediate investor test is execution across several programs rather than one isolated sales figure. Argenx expects combined research and development plus selling and general administrative expenses of approximately USD 4 billion for full-year 2026, including costs from the Forte transaction, according to GlobeNewswire.

Two reporting dates are set

The next scheduled company dates are February 25, 2027, for full-year 2026 results and the fourth-quarter business update, followed by April 29, 2027, for first-quarter 2027 results. Both dates were included in the company's financial calendar published with the third-quarter release.

Stock price in euros

argenx stock was trading at EUR 779.30 at Lang & Schwarz on October 23, 2026 at 10:10 a.m. CEST. The primary listing is on Nasdaq, where the last quoted price was USD 875.76 on October 22, 2026 at 4:00 p.m. ET. The USD 661.85 to USD 1,072.75 52-week range and USD 55.1 billion market capitalization are dated to that quote.

The further course of trading is shown by the continuously updated real-time quote of argenx stock.